TRIAL PRODUCT CLADE CANDIDATE START END COUNTRIES NUMBER OF VOLUNTEERS PHASE IMMUNE RESPONSE RESULT
VAX003 AIDSVAX B/E Recombinant gp120 Protein 1998 2003 Canada, Netherlands, Puerto Rico, US 5,417 III T cell, Antibodies No Efficacy
VAX004 AIDSVAX B/E Recombinant gp120 Protein 1998 2003 Thailand 2,546 III T cell, Antibodies No Efficacy
STEP MRK-Ad5 B Ad5     gag/pol/nef 2005 2007 Australia, Brazil, Canada, Dominican Republic, Haiti, Jamaica, Peru, Puerto Rico, USA 3,000 IIb T cell No Efficacy
PHAMBILI MRK-Ad5 B Ad5     gag/pol/nef 2005 2007 South Africa 801 IIb T cell No Efficacy
RV144 ALVAC-HIV and AIDSVAX    B/E Recombinant gp120 Protein + Canary pox vector 2003 2009 Thailand 16,402 III T cell, Antibodies 31.20%
HVTN 505 DNA and Ad5 A/B/C DNA Ad5   gag/pol/nef 2009 2013 USA 2,500 IIb T cell, Antibodies No Efficacy
Table 1: Synopsis of completed Phase IIb/III efficacy trials of HIV vaccine.